CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 194 enrolled
Drug / intervention
Latanoprost ophthalmic solution +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04405245
NCT04405245Phase 2Completed
CompareCT.gov

Phase 2 Multi-Center, Double-Masked, Randomized, 28-Day Study to Assess the Efficacy, Safety and Tolerability of Single or Twice Daily Doses of AKB-9778 Ophthalmic Solution as an Adjunct to Latanoprost in Patients With Ocular Hypertension (OHT) or Open Angle Glaucoma (OAG)

EyePoint Pharmaceuticals, Inc.·interventional·Posted May 28, 2020·Updated May 25, 2023

In Brief

A Phase 2 clinical trial evaluating Latanoprost ophthalmic solution, AKB-9778 4%, and 1 other intervention for Ocular Hypertension and Primary Open Angle Glaucoma. Completed, enrolled 194 participants across 21 sites.

Detailed Summary

This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic Solution 4.0% administered once (AM) or twice (AM \& PM) daily when used as an adjunctive therapy to latanoprost ophthalmic solution 0.005% once daily (PM) in subjects with elevated IOP due to OAG or OHT.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Primary Open Angle Glaucoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMay 28, 2020
Enrollment StartJun 6, 2020
Primary CompletionNov 5, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.1 years ago

Interventions

Latanoprost ophthalmic solutiondrug

Latanoprost opthalmic solution to be dosed once daily

AKB-9778 4%drug

Razuprotafib opthalmic solution

Placebodrug

placebo for razuprotafib opthalmic solution